AstraZeneca (2017) developed imidazo[4,5-c]quinolin-2-one derivatives that inhibit ATR, ATM, and mTOR kinases, demonstrating potential for treating breast cancer and ductal carcinoma. Here, ATM is linked to breast carcinoma.